Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label pediatric belumosudil study for chronic graft-versus-host disease
MOH_2025-10-26_015405Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of belumosudil in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Sanofi. Primary endpoint: Recommended pediatric equivalent dose. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on MOH_2025-10-26_015405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-26_015405.